- Home
- News
- latamerica
- pharmaceutical compounding
Refine by
Pharmaceutical Compounding Articles & Analysis
26 news found
Versatile compound shows promise in drug synthesis, metal chelation, antioxidant activity, and moreChangsha, China – May 22, 2025– Hunan Huateng Pharmaceutical Co., Ltd., a leading global supplier of PEG derivatives and pharmaceutical intermediates, is proud to offer high-purity N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7) to researchers ...
Huateng Pharma, a distinguished provider of premium pharmaceutical intermediates, proudly unveils its latest breakthrough: Semaglutide Side Chain. This groundbreaking addition to Huateng Pharma's esteemed portfolio signifies a remarkable leap forward in pharmaceutical innovation, showcasing a diverse array of compounds including AEEA-AEEA (CAS ...
It helps assess the purity and authenticity of pharmaceutical compounds, ensuring compliance with regulatory standards. Another essential test is the melting point test, which determines the temperature at which a substance changes from a solid to a liquid state. ...
The conference, which is one of the largest gatherings of chemists and scientific researchers in the world, provided Alfa Chemistry with an opportunity to showcase its latest products and technologies, including its revolutionary isotope compounds, active pharmaceutical ingredients (APIs), extracted peptides, protection reagents, nanomaterials, precious metal ...
Spectra do not provide molecular weight and structure information of unknown compounds, making it difficult for qualitative analysis. However, LC-MS/MS uses tandem mass spectrometry to access molecular ion peaks and fragment ion peaks, qualitatively and quantitatively analyzing molecules. In addition, sample identification and accurate quantitation can be further enhanced by ...
(NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the initiation of the first Phase 3 clinical trial of its lead candidate CTx-1301, a novel, investigational, trimodal, extended release tablet ...
Application No. 17/546,880 filed on December 9, 2021 and titled Complexing Agent Salt Formulations of Pharmaceutical Compounds. Bexson’s formulation platform, branded as SeValent, is the basis for the Company’s lead ketamine therapy, BB106. ...
“This divestment is part of the ongoing transformation of our pharmaceuticals business, which focuses on key areas of healthcare innovation,” said Marianne De Backer, PhD, MBA, Member of the Executive Committee and EVP, Head Strategy and Business Development & Licensing and Open Innovation, Pharmaceuticals Division of Bayer AG. ...
ByBayer AG
Its comprehensive fermentation CDMO services and small microbial molecules have delivered tremendous value to the pharmaceutical industry. And the future looks even better. Pharmaceutical enterprises have been confronted with numerous challenges, such as rising cost pressures and uncertainty in the upstream supply of APIs, antibodies, enzymes, therapeutic ...
Below is a detailed list of BOC Sciences highlights presented at the BIO conference this year: Fermentation for APIs & Bioactive Metabolites: Multiple strain development strategies including mutation, selection, cloning, and genetic recombination Extensive product portfolio of metabolites up to kilogram scales Successful delivery in 20+ high potent API projects Preclinical CRO Services: ...
Many drug candidates unfortunately stopped their way ahead from the discovery pipeline just simply because they are poorly water-soluble, which further leads to poor bioavailability. Pharmaceutical excipients play magic roles to achieve better drug delivery and adoption. ...
” “With the ARASENS results in mHSPC adding to the existing Phase III ARAMIS data in non-metastatic castration-resistant prostate cancer (nmCRPC), darolutamide has now shown positive data in two pivotal clinical trials for patients across these key disease stages in prostate cancer,” said Robert LaCaze, Member of the Executive Committee of Bayer’s ...
ByBayer AG
GLK-302 is the second investigational drug candidate utilizing Glaukos’ iLution platform’s patented cream-based drug formulations that are applied to the outer surface of the eyelid for dropless transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. GLK-302’s active pharmaceutical ...
GLK-301 is the first investigational drug candidate utilizing Glaukos’ iLution platform’s patented cream-based drug formulations that are applied to the outer surface of the eyelid for dropless transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. GLK-301’s active pharmaceutical ingredient ...
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning Life Science/Pharmaceutical company developing formulations combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced the filing of its International Patent, trade named Mentanine, which has ...
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning Life Science/Pharmaceutical company developing health and wellness products combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced that Rob Rinderman has joined CanaQuest as its new Director of ...
CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the “Company” or “CanaQuest“), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced it has been awarded the International CBD Life Science R & D Excellence Award ...
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that Fundamental Research Corp (“FRC”), one of the world’s largest ...
Canaquest Medical Corp (OTC Markets: “CANQF”) (the “Company” or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), is pleased to announce its new partnership with the Canadian Cannabis Dispute ...
Hanover, Germany, October 22, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company, focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced a publication in the European Heart Journal (doi:10.1093/eurheartj/ehaa791) demonstrating that repeated treatment with its lead compound ...